Stay informed

[Translate to English:] Fotocredit: Peter Baier
Corporate Communications

Mag. Birgit Schiehauer

"Communication connects people. For me, it is the key to successful relationships with our customers, but also with our employees. And I love to communicate. That is my passion.

Richter Pharma is a company that is constantly changing and growing successfully. Everyone in the company works for this with unparalleled dedication. To be able to capture these successes in words and pictures and also to present them to the public makes me proud.

I look forward to hearing from you."


Press 2023

Richter Pharma triples new production in Wels by 35 million euros

Richter Pharma AG in Wels is relying on Upper Austria as a business location: it is modernizing and expanding its veterinary pharmaceutical production with a new production complex in Wels' Durisolstraße. The investment volume amounts to 35 million euros, and the new building is scheduled to be occupied in 2025. On January 17, 2023, the Upper Austrian Governor Mag. Thomas Stelzer, the Mayor of Wels Dr. Andreas Rabl, Richter Pharma owner Mag. pharm. Florian Fritsch and Richter Pharma CEO Roland Huemer held the groundbreaking ceremony.

Press release on the 1st groundbreaking ceremony (German)

Long-term CEO Roland Huemer and new COO Andreas Schilde continue Richter Pharma's successful path as a management board team

Richter Pharma AG has defined its management board team for the coming years. Richter Pharma owner and head of the supervisory board Florian Fritsch focuses on continuity:

The long-standing CEO Roland Huemer is confirmed again in his function by the Supervisory Board and his mandate is extended for another 5 years. At his side since April 03, 2023 is Andreas Schilde as the new COO, who again strengthens the Group's Management Board.

Press release on the expansion of the Executive Board (German)

Richter Pharma AG defies challenging general conditions and pushes ahead strongly with growth and investment course

Richter Pharma AG consistently pursued its strategic path in 2022 despite the tense cost and supply chain situation:

  • The construction of a new production complex to triple manufacturing capacity in Wels was put on track and started in January 2023.
  • The bundling of the entire veterinary production in the new subsidiary VetViva Richter GmbH was successfully implemented as of April 1, 2023.
  • In terms of business management, 2022 was also a solid year for Richter Pharma: Sales increased to EUR 682 million. The EBITDA development could not escape the challenging market conditions and decreased by 12% to EUR 11 million.